Literature DB >> 12950441

Proteomics in Alzheimer's disease: insights into potential mechanisms of neurodegeneration.

D Allan Butterfield1, Debra Boyd-Kimball, Alessandra Castegna.   

Abstract

Proteomics involves the identification of unknown proteins following their separation, often using two-dimensional electrophoresis, digestion of particular proteins of interest by trypsin, determination of the molecular weight of the resulting peptides, and database searching to make the identification of the proteins. Application of proteomics to Alzheimer's disease (AD), the major dementing disorder of the elderly, has just begun. Differences in protein expression and post-translational modification (mostly oxidative modification) of proteins from AD brain and peripheral tissue, as well as in brain from rodent models of AD, have yielded insights into potential molecular mechanisms of neurodegeneration in this dementing disorder. This review surveys the proteomics studies relevant to AD, from which new understandings of the pathology, biochemistry, and physiology of AD are beginning to emerge.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12950441     DOI: 10.1046/j.1471-4159.2003.01948.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  33 in total

Review 1.  Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean?

Authors:  Barry Halliwell; Matthew Whiteman
Journal:  Br J Pharmacol       Date:  2004-05       Impact factor: 8.739

Review 2.  Proteomic studies on the development of the central nervous system and beyond.

Authors:  Chenggang Zhang
Journal:  Neurochem Res       Date:  2010-06-25       Impact factor: 3.996

3.  Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.

Authors:  Marzia Perluigi; Rukhsana Sultana; Giovanna Cenini; Fabio Di Domenico; Maurizio Memo; William M Pierce; Raffaella Coccia; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2009-06-01       Impact factor: 3.494

4.  Identification of AGE-modified proteins in SH-SY5Y and OLN-93 cells.

Authors:  André K Langer; H Fai Poon; Gerald Münch; Bert C Lynn; Thomas Arendt; D Allan Butterfield
Journal:  Neurotox Res       Date:  2006-06       Impact factor: 3.911

Review 5.  Genetics, transcriptomics, and proteomics of Alzheimer's disease.

Authors:  Andreas Papassotiropoulos; Michael Fountoulakis; Travis Dunckley; Dietrich A Stephan; Eric M Reiman
Journal:  J Clin Psychiatry       Date:  2006-04       Impact factor: 4.384

Review 6.  Biomarkers of Alzheimer disease in plasma.

Authors:  Michael C Irizarry
Journal:  NeuroRx       Date:  2004-04

7.  An optimal protocol to analyze the rat spinal cord proteome.

Authors:  F Gil-Dones; S Alonso-Orgaz; G Avila; T Martin-Rojas; V Moral-Darde; G Barroso; F Vivanco; J Scott-Taylor; M G Barderas
Journal:  Biomark Insights       Date:  2009-10-28

8.  Acrolein induces selective protein carbonylation in synaptosomes.

Authors:  C F Mello; R Sultana; M Piroddi; J Cai; W M Pierce; J B Klein; D A Butterfield
Journal:  Neuroscience       Date:  2007-06-14       Impact factor: 3.590

Review 9.  Oxidatively modified proteins in Alzheimer's disease (AD), mild cognitive impairment and animal models of AD: role of Abeta in pathogenesis.

Authors:  Rukhsana Sultana; Marzia Perluigi; D Allan Butterfield
Journal:  Acta Neuropathol       Date:  2009-03-14       Impact factor: 17.088

Review 10.  The 2013 SFRBM discovery award: selected discoveries from the butterfield laboratory of oxidative stress and its sequela in brain in cognitive disorders exemplified by Alzheimer disease and chemotherapy induced cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2014-07-01       Impact factor: 7.376

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.